Skip to Content

H.R. 1965, “Patient Protection and Innovative Biologic Medicines Act of 2007”

U.S. House of Representatives
April 19, 2007

110TH CONGRESS 1ST SESSION H. R. 1956 To amend the Public Health Service Act to provide for the approval of similar biological products, and for other purposes. IN THE HOUSE OF REPRESENTATIVES APRIL 19, 2007

H.R. Hearing on Safe and Affordable Biotech Drugs: The Need for a Generic Pathway

U.S. House of Representatives, Committee on Oversight and Government Reform
March 26, 2007

SAFE AND AFFORDABLE BIOTECH DRUGS: THE NEED FOR A GENERIC PATHWAY HEARING BEFORE THE COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM HOUSE OF REPRESENTATIVES ONE HUNDRED TENTH CONGRESS FIRST SESSION MARCH 26, 2007 Serial No. 110–43

H.R. Hearing on Challenges and Solutions to Health Insurance Coverage for Small Businesses

U.S. House of Representatives, Committee on Small Business
March 14, 2007

FULL COMMITTEE HEARING ON CHALLENGES AND SOLUTIONS TO HEALTH INSURANCE COVERAGE FOR SMALL BUSINESSES COMMITTEE ON SMALL BUSINESS UNITED STATES HOUSE OF REPRESENTATIVES ONE HUNDRED TENTH CONGRESS FIRST SESSION MARCH 14, 2007

Senate Committee Hearing 110-375, Examining FDA Follow-On Biologics

Senate Committee on Health, Education, Labor, and Pensions
March 8, 2007

HEARING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE ONE HUNDRED TENTH CONGRESS FIRST SESSION ON EXAMINING FOOD AND DRUG ADMINISTRATION FOLLOW-ON BIOLOGICS, GENERALLY REFERRED TO AS A BIOTECHNOLOGY-DERIVED PROTEIN DRUG (OR BIOLOGIC) THAT IS COMPARABLE TO A NOVEL, PREVIOUSLY APPROVED BIOLOGIC AND THAT IS APPROVED